Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Neoplasms

abstract

  • Pediatric patients tolerate 10 mg/kg of lexatumumab administered once every 14 days, the maximum-tolerated dose identified in adults. The drug seems to mediate some clinical activity in pediatric solid tumors and may work with radiation to enhance antitumor effects.

publication date

  • November 20, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3494837

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.44.1055

PubMed ID

  • 23071222

Additional Document Info

start page

  • 4141

end page

  • 7

volume

  • 30

number

  • 33